Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hims & Hers Health's gross profit for the
three
months ended in Jun. 2026 was CHF384 Mil. Hims & Hers Health's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was CHF1,403 Mil.
Hims & Hers Health (XSWX:HIMS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Hims & Hers Health had a gross margin of 63.83% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Hims & Hers Health Gross Profit Related Terms
Hims & Hers Health Gross Profit Historical Data
* Premium members only.
The historical data trend for Hims & Hers Health's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:HIMS vs LNTH, AMRX, LQDA: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hims & Hers Health Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Gross Profit distribution charts can be found below:
* The bar in red indicates where Hims & Hers Health's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,403 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Hims & Hers Health (XSWX:HIMS) has a Gross Profit of CHF1,403 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Hims & Hers Health and its competitors.
Is Hims & Hers Health's Gross Profit too high?
Hims & Hers Health's current Gross Profit is CHF1,403 Mil. Overall, Hims & Hers Health has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Gross Profit compare to LNTH and AMRX?
Hims & Hers Health's Gross Profit of CHF1,403 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Hims & Hers Health and its competitors. Hims & Hers Health's current Gross Profit is CHF1,403 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Hims & Hers Health (XSWX:HIMS) has a current Gross Profit of CHF1,403 Mil. The stock's GF Value™ is CHF35.29, compared to a current price of CHF23.56 — trading 33.3% below its estimated fair value. The current Gross Profit is CHF1,403 Mil. Hims & Hers Health's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Hims & Hers Health (XSWX:HIMS), the current Gross Profit is CHF1,403 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hims & Hers Health (XSWX:HIMS) Overvalued in 2026?
Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued.
The current stock price of CHF23.56 is trading 33.3% below its estimated GF Value™ of CHF35.29.
Key valuation signals for XSWX:HIMS:
Gross Profit: CHF1,403 Mil
GF Value™: CHF35.29 vs. price of CHF23.56 (33.3% below fair value)
No single metric tells the full story. See the XSWX:HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
78GF Score
Get the complete analysis for XSWX:HIMS
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:HIMS has been successfully added to your 
